Crescent Biopharma launches underwritten public offering of ordinary shares, pre-funded warrants - CBIO News | RalliesCrescent Biopharma launches underwritten public offering of ordinary shares, pre-funded warrants
C
CBIO• Public offering details
- Crescent Biopharma launched an underwritten public offering of ordinary shares or pre-funded warrants to buy ordinary shares.
- Underwriters hold a 30-day option to purchase up to 15% more ordinary shares at the offering price, less discounts.
- Jefferies, TD Cowen, Guggenheim Securities and Cantor are leading the deal; LifeSci Capital acts as passive book-runner.
- Shares and pre-funded warrants are being sold by the company under an effective Form S-3 shelf registration statement.
•
